Phases, active trials: Phase 1: 2, Phase 2: 24, Phase 3: 45, Other: 55
Takeda's pipeline spans oncology, gastroenterology, rare disease, and plasma-derived therapies. Their oncology franchise includes Alunbrig (brigatinib) for ALK-positive NSCLC, competitive with Lorbrena in the post-crizotinib setting, and Ninlaro (ixazomib), the first oral proteasome inhibitor for multiple myeloma. In gastroenterology, Entyvio (vedolizumab) for IBD has one of the most active label expansion programs in the specialty. Their rare disease portfolio (alpha-1 antitrypsin deficiency, Fabry disease, hereditary angioedema) continues generating Phase 3 trials. Takeda is also advancing TAK-279 (zasocitinib), a TYK2 inhibitor, as a potential competitor to Bristol Myers Squibb's deucravacitinib in psoriasis and PsA.
- Oncology (NSCLC, multiple myeloma, lymphoma)
- Gastroenterology / IBD
- Rare / plasma-derived
- Neuroscience
- Immunology (TYK2, IL)
- Alunbrig (brigatinib): ALK inhibitor, NSCLC
- Ninlaro (ixazomib): oral proteasome inhibitor, myeloma
- Entyvio (vedolizumab): α4β7 integrin, IBD/Crohn's/UC
- TAK-279 (zasocitinib): TYK2 inhibitor, psoriasis/PsA
- Fruquintinib: VEGFR 1/2/3 inhibitor, CRC (via Zymeworks)
- TAK-981: SUMO pathway inhibitor, lymphoma
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Gaucher Disease Outcome Survey (GOS) NCT03291223 | Primary completion moved at least 2 years later | Recruiting |
13 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer NCT02716116 | Oct 31, 2026 · Estimated | Phase 1/2 |
8 more on the Completions page. See the calendar →
Monitor the Takeda pipeline daily
Get a daily digest when Takeda registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Crohn's Disease | 13 |
| Ulcerative Colitis | 9 |
| Hereditary Angioedema (HAE) | 6 |
| Cytomegalovirus (CMV) | 5 |
| Dengue Fever | 5 |
| Alpha1-Antitrypsin Deficiency | 4 |
| Colorectal Cancer | 4 |
| Multiple Myeloma | 4 |
Takeda's TYK2 inhibitor zasocitinib is the most significant competitive threat to BMS's deucravacitinib (Sotyktu) in the psoriasis/PsA space. Any dermatology-focused company should monitor Takeda's Phase 3 program. In GI, new Entyvio combinations and IBD programs are closely watched by companies developing competing gut-selective biologics.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Takeda's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Takeda may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Takeda pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in… NCT07445087 | Recruiting | Trial sites expanded: 0 → 3 locations | 2026-10-16 |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors NCT07205718 | Recruiting | Trial arms changed: 6 → 5 | 2026-10-15 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not… NCT06671496 | Active, Not Recruiting | Trial sites reduced: 123 → 120 locations | 2026-10-15 |
| A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent… NCT06980480 | Recruiting | Trial sites expanded: 56 → 65 locations | 2026-10-14 |
| A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During… NCT04961840 | Active, Not Recruiting | Study completion pushed from Dec 31, 2026 to Jun 30, 2027 | 2026-10-14 |
Each trial page shows every change DataLookout has recorded for that trial.